Literature DB >> 19266600

Docosahexaenoic acid suppresses arachidonic acid-induced proliferation of LS-174T human colon carcinoma cells.

Piet Habbel1, Karsten H Weylandt, Katja Lichopoj, Johannes Nowak, Martin Purschke, Jing-Dong Wang, Cheng-Wei He, Daniel C Baumgart, Jing X Kang.   

Abstract

AIM: To investigate the impact of arachidonic acid (AA) and docosahexaenoic acid (DHA) and their combination on colon cancer cell growth.
METHODS: The LS-174T colon cancer cell line was used to study the role of the prostaglandin precursor AA and the omega-3 polyunsaturated fatty acid DHA on cell growth. Cell viability was assessed in XTT assays. For analysis of cell cycle and cell death, flow cytometry and DAPI staining were applied. Expression of cyclooxygenase-2 (COX-2), p21 and bcl-2 in cells incubated with AA or DHA was examined by real-time RT-PCR. Prostaglandin E(2) (PGE(2)) generation in the presence of AA and DHA was measured using a PGE(2)-ELISA.
RESULTS: AA increased cell growth, whereas DHA reduced viability of LS 174T cells in a time- and dose-dependent manner. Furthermore, DHA down- regulated mRNA of bcl-2 and up-regulated p21. Interestingly, DHA was able to suppress AA-induced cell proliferation and significantly lowered AA-derived PGE(2) formation. DHA also down-regulated COX-2 expression. In addition to the effect on PGE(2) formation, DHA directly reduced PGE(2)-induced cell proliferation in a dose-dependent manner.
CONCLUSION: These results suggest that DHA can inhibit the pro-proliferative effect of abundant AA or PGE(2).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19266600      PMCID: PMC2655186          DOI: 10.3748/wjg.15.1079

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  30 in total

1.  Docosahexaenoic acid is a potent inducer of apoptosis in HT-29 colon cancer cells.

Authors:  Z Y Chen; N W Istfan
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2000-11       Impact factor: 4.006

2.  Role of cyclooxygenase 2 in protein kinase C beta II-mediated colon carcinogenesis.

Authors:  Wangsheng Yu; Nicole R Murray; Capella Weems; Lu Chen; Huiping Guo; Richard Ethridge; Jeffrey D Ceci; B Mark Evers; E Aubrey Thompson; Alan P Fields
Journal:  J Biol Chem       Date:  2002-12-11       Impact factor: 5.157

3.  Docosahexaenoic acid regulated genes and transcription factors inducing apoptosis in human colon cancer cells.

Authors:  B A Narayanan; N K Narayanan; B S Reddy
Journal:  Int J Oncol       Date:  2001-12       Impact factor: 5.650

4.  The role of cyclooxygenase in n-6 and n-3 polyunsaturated fatty acid mediated effects on cell proliferation, PGE(2) synthesis and cytotoxicity in human colorectal carcinoma cell lines.

Authors:  Yvonne E M Dommels; Merel M G Haring; Nynke G M Keestra; Gerrit M Alink; Peter J van Bladeren; Ben van Ommen
Journal:  Carcinogenesis       Date:  2003-03       Impact factor: 4.944

5.  Modulation of inducible nitric oxide synthase and related proinflammatory genes by the omega-3 fatty acid docosahexaenoic acid in human colon cancer cells.

Authors:  Bhagavathi A Narayanan; Narayanan K Narayanan; Barbara Simi; Bandaru S Reddy
Journal:  Cancer Res       Date:  2003-03-01       Impact factor: 12.701

6.  Prostaglandin E2 stimulates the growth of colon cancer cells via induction of amphiregulin.

Authors:  Jinyi Shao; Sean B Lee; Huiping Guo; B Mark Evers; Hongmiao Sheng
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

7.  Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas.

Authors:  C E Eberhart; R J Coffey; A Radhika; F M Giardiello; S Ferrenbach; R N DuBois
Journal:  Gastroenterology       Date:  1994-10       Impact factor: 22.682

8.  Prostaglandin E2 synergistically enhances receptor tyrosine kinase-dependent signaling system in colon cancer cells.

Authors:  Jinyi Shao; B Mark Evers; Hongmiao Sheng
Journal:  J Biol Chem       Date:  2004-01-23       Impact factor: 5.157

9.  Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer.

Authors:  S L Kargman; G P O'Neill; P J Vickers; J F Evans; J A Mancini; S Jothy
Journal:  Cancer Res       Date:  1995-06-15       Impact factor: 12.701

10.  Eicosapentaenoic acid (EPA) reduces crypt cell proliferation and increases apoptosis in normal colonic mucosa in subjects with a history of colorectal adenomas.

Authors:  E D Courtney; S Matthews; C Finlayson; D Di Pierro; A Belluzzi; E Roda; J Y Kang; R J Leicester
Journal:  Int J Colorectal Dis       Date:  2007-01-10       Impact factor: 2.796

View more
  5 in total

1.  Serum metabolite profiling of familial adenomatous polyposis using ultra performance liquid chromatography and tandem mass spectrometry.

Authors:  Liyan Sun; Qian Kang; Yuanming Pan; Na Li; Xin Wang; Yuqi He; Haihong Wang; Dongliang Yu; Hui Xie; Lang Yang; Youyong Lu; Peng Jin; Jianqiu Sheng
Journal:  Cancer Biol Ther       Date:  2019-04-14       Impact factor: 4.742

2.  Treatment of LS174T colorectal cancer stem-like cells with n-3 PUFAs induces growth suppression through inhibition of survivin expression and induction of caspase-3 activation.

Authors:  Mohammad Reza Sam; Parinaz Ahangar; Vahid Nejati; Reza Habibian
Journal:  Cell Oncol (Dordr)       Date:  2015-12-15       Impact factor: 6.730

Review 3.  ω3 Polyunsaturated Fatty Acids as Immunomodulators in Colorectal Cancer: New Potential Role in Adjuvant Therapies.

Authors:  Stefania Miccadei; Roberta Masella; Anna Maria Mileo; Sandra Gessani
Journal:  Front Immunol       Date:  2016-11-15       Impact factor: 7.561

Review 4.  The Role of Pro-Resolving Lipid Mediators in Colorectal Cancer-Associated Inflammation: Implications for Therapeutic Strategies.

Authors:  Federica Ungaro; Silvia D'Alessio; Silvio Danese
Journal:  Cancers (Basel)       Date:  2020-07-26       Impact factor: 6.639

5.  Fatty acids in habitual diet, plasma phospholipids, and tumour and normal colonic biopsies in young colorectal cancer patients.

Authors:  Paula Berstad; Espen Thiis-Evensen; Morten H Vatn; Kari Almendingen
Journal:  J Oncol       Date:  2012-12-23       Impact factor: 4.375

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.